Treats multiple inflammatory nodules with a diameter of 5 mm or greater. ANDA 76356, held by Teva Pharms USA. Isotretinoin.
As of Nov 16, 2026, ANDA 76356 (Claravis), held by Teva Pharms USA, was first approved by FDA on Apr 11, 2003, with 25 approved supplements and 0 published complete response letters.
Claravis (isotretinoin capsules USP) is indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Claravis is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use: If a second course of Claravis treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15 to 20-week course of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 11, 2003 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Claravis10MG · capsule;oral | Isotretinoin | Rx |
| Oct 7, 2026 | Supplement 64REMS | Approved | None posted |
| Aug 21, 2026 | Supplement 63Labeling · Standard review | Approved | None posted |
| Feb 9, 2026 | Supplement 57REMS | Approved | None posted |
| Mar 4, 2024 | Supplement 51Labeling · Standard review | Approved | None posted |
| Mar 24, 2023 | Supplement 55REMS | Approved | None posted |
| Oct 6, 2022 | Supplement 53REMS | Approved | None posted |
| Aug 23, 2022 | Supplement 50Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 48Labeling · Standard review | Approved | None posted |
| Oct 8, 2021 | Supplement 47REMS | Approved | None posted |
| Dec 9, 2020 | Supplement 45REMS | Approved | None posted |
| Aug 31, 2018 | Supplement 40Labeling · Standard review | Approved | None posted |
| May 2, 2018 | Supplement 38Labeling · Standard review | Approved | None posted |
| Apr 23, 2018 | Supplement 39REMS | Approved | None posted |
| Jun 17, 2017 | Supplement 35REMS | Approved | None posted |
| Jul 8, 2016 | Supplement 34REMS | Approved | None posted |
| Feb 4, 2016 | Supplement 33REMS | Approved | None posted |
| Sep 3, 2015 | Supplement 32REMS | Approved | None posted |
| Jul 20, 2015 | Supplement 27Labeling · Standard review | Approved | None posted |
| Apr 12, 2012 | Supplement 26REMS | Approved | None posted |
| Oct 22, 2010 | Supplement 17REMS | Approved | None posted |
| Mar 25, 2010 | Supplement 16Labeling | Approved | None posted |
| Nov 2, 2007 | Supplement 13Labeling | Approved | None posted |
| Feb 2, 2007 | Supplement 12Labeling | Approved | None posted |
| Feb 2, 2007 | Supplement 9Labeling | Approved | None posted |
| Aug 12, 2005 | Supplement 6Labeling | Approved | None posted |
| Apr 11, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters